Today: 21 December 2025
Subscribe
Browse Category

NYSE:PFE News 13 November 2025 - 21 November 2025

Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Metsera (MTSR) News Today, 21 November 2025: Pfizer’s $10 Billion Buyout, $6 Billion Bond Sale and What It Means for Investors

Pfizer has closed its up to $10 billion acquisition of Metsera (MTSR) and raised $6 billion in bonds to help fund the deal. Here’s what today’s developments mean for former Metsera shareholders, Pfizer investors and the future of the obesity
21 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer Stock News Today (PFE): Texas ADHD Settlement, New Antibody Partnership and Obesity Push – November 19, 2025

Pfizer (NYSE: PFE) headlines today include a $41.5 million ADHD drug settlement with Texas, a new antibody discovery deal with Nona Biosciences, and fresh guidance on cost cuts and obesity drugs from the Jefferies Healthcare Conference — here’s what it
19 November 2025
 ·  ·  ·  ·  · 
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer Stock Today (Nov. 18, 2025): PFE steadies near $25 as Pfizer launches multi‑tranche bond sale to help fund Metsera deal

Summary Live PFE snapshot (intraday) New today: Pfizer sells debt to fund Metsera Pfizer began marketing a U.S. dollar investment‑grade bond expected to raise at least $5 billion, with the deal structured in as many as seven parts. Early discussions
18 November 2025
 ·  ·  ·  ·  ·  · 
Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Metsera (MTSR) Delists as Pfizer Closes Up to $10 Billion Obesity Drug Deal – All the Key Updates on November 17, 2025

Pfizer’s acquisition of Metsera, Inc. (formerly NASDAQ: MTSR) is now effectively complete, Metsera’s stock has been delisted, major index providers are removing the name, and antitrust scholars are using the failed Novo Nordisk bid as a case study in “attempted
17 November 2025
 ·  ·  ·  ·  ·  · 
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters+1 The move deepens J&J’s bet on
17 November 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Metsera Inc. (NASDAQ: MTSR) stops trading today, November 14, 2025, as Pfizer closes its up to $10 billion obesity-drug acquisition. Here’s what Metsera shareholders and obesity-market investors need to know about the deal terms, CVR, delisting, and future milestones. Date:
14 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock (PFE) Before the Bell on November 14, 2025: Metsera Deal Closes, BioNTech Stake Cut and Guidance Raised

As Wall Street heads into Friday’s session, Pfizer stock is trading slightly lower in premarket action while investors digest a trio of big developments: the completed acquisition of obesity‑drug developer Metsera, a sharp reduction in Pfizer’s stake in BioNTech, and
14 November 2025
 ·  ·  ·  ·  ·  · 
Pfizer Stock Plunge and Promise: Vaccine Slump, Weight-Loss War, and a $10B Gamble – Is PFE Poised for a Comeback?

Pfizer Stock Today, November 13, 2025: BioNTech Stake Sale, Metsera Deal and a 6%+ Dividend Put PFE Back in Focus

Pfizer stock (NYSE: PFE) is trading higher today as investors digest a fresh batch of headlines: a planned sale of the company’s remaining stake in Covid-19 vaccine partner BioNTech, ongoing reaction to its $10 billion Metsera obesity-drug deal, and renewed
13 November 2025
 ·  ·  ·  ·  ·  · 
1 2 3 4 5 6 … 8
Go toTop